Influenza-like illness is associated with high pneumococcal carriage density in Malawian children.
Carriage density
Children
IL-8
Influenza-like illness
Pneumococcal
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
09
04
2020
revised:
25
06
2020
accepted:
27
06
2020
pubmed:
28
7
2020
medline:
19
3
2021
entrez:
26
7
2020
Statut:
ppublish
Résumé
High pneumococcal carriage density is a risk factor for invasive pneumococcal disease (IPD) and transmission, but factors that increase pneumococcal carriage density are still unclear. We undertook a cross-sectional study to evaluate the microbial composition, cytokine levels and pneumococcal carriage densities in samples from children presenting with an influenza-like illness (ILI) and asymptomatic healthy controls (HC). The proportion of children harbouring viral organisms (Relative risk (RR) 1.4, p = 0.0222) or ≥ 4 microbes at a time (RR 1.9, p < 0.0001), was higher in ILI patients than HC. ILI patients had higher IL-8 levels in nasal aspirates than HC (median [IQR], 265.7 [0 - 452.3] vs. 0 [0 - 127.3] pg/ml; p = 0.0154). Having an ILI was associated with higher pneumococcal carriage densities compared to HC (RR 4.2, p < 0.0001). These findings suggest that children with an ILI have an increased propensity for high pneumococcal carriage density. This could in part contribute to increased susceptibility to IPD and transmission in the community.
Sections du résumé
BACKGROUND
High pneumococcal carriage density is a risk factor for invasive pneumococcal disease (IPD) and transmission, but factors that increase pneumococcal carriage density are still unclear.
METHODS
We undertook a cross-sectional study to evaluate the microbial composition, cytokine levels and pneumococcal carriage densities in samples from children presenting with an influenza-like illness (ILI) and asymptomatic healthy controls (HC).
RESULTS
The proportion of children harbouring viral organisms (Relative risk (RR) 1.4, p = 0.0222) or ≥ 4 microbes at a time (RR 1.9, p < 0.0001), was higher in ILI patients than HC. ILI patients had higher IL-8 levels in nasal aspirates than HC (median [IQR], 265.7 [0 - 452.3] vs. 0 [0 - 127.3] pg/ml; p = 0.0154). Having an ILI was associated with higher pneumococcal carriage densities compared to HC (RR 4.2, p < 0.0001).
CONCLUSION
These findings suggest that children with an ILI have an increased propensity for high pneumococcal carriage density. This could in part contribute to increased susceptibility to IPD and transmission in the community.
Identifiants
pubmed: 32711042
pii: S0163-4453(20)30495-3
doi: 10.1016/j.jinf.2020.06.079
pmc: PMC7375306
pii:
doi:
Substances chimiques
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
549-556Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCEZID CDC HHS
ID : U01 CK000146
Pays : United States
Organisme : Wellcome Trust
ID : 101113/Z/13/Z084
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 105831/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204457/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P011284/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest We declare no competing interests.
Références
J Infect. 2017 Jan;74(1):29-41
pubmed: 27667752
Sci Rep. 2018 Jul 23;8(1):11030
pubmed: 30038420
Am J Respir Crit Care Med. 2019 Aug 1;200(3):359-369
pubmed: 30625278
BMC Infect Dis. 2016 Mar 17;16:129
pubmed: 26983753
Infect Immun. 2016 Mar 24;84(4):906-16
pubmed: 26787714
Anal Biochem. 1994 Feb 1;216(2):276-84
pubmed: 8179182
BMJ Open. 2019 Nov 13;9(11):e030981
pubmed: 31727654
Bull World Health Organ. 2018 Feb 1;96(2):122-128
pubmed: 29403115
Nat Commun. 2020 May 6;11(1):2222
pubmed: 32376860
Microbiol Insights. 2018 Feb 13;11:1178636118758651
pubmed: 29467579
Immunobiology. 2010 Apr;215(4):251-63
pubmed: 20071053
Clin Microbiol Infect. 2014 Dec;20(12):O1145-51
pubmed: 24995531
Pediatr Infect Dis J. 2011 Jan;30(1):11-8
pubmed: 20686433
Lancet Infect Dis. 2017 Oct;17(10):1042-1052
pubmed: 28818544
Trends Microbiol. 2013 Mar;21(3):129-35
pubmed: 23273566
Clin Vaccine Immunol. 2012 Apr;19(4):499-507
pubmed: 22336290
Clin Infect Dis. 2014 May;58(10):e137-45
pubmed: 24496208
Am J Respir Crit Care Med. 2014 May 15;189(10):1250-9
pubmed: 24749506
J Clin Microbiol. 2010 Nov;48(11):3836-42
pubmed: 20739481
Thorax. 2008 Aug;63(8):690-7
pubmed: 18250183
Clin Infect Dis. 2018 Mar 5;66(6):865-876
pubmed: 29045699
Nat Immunol. 2018 Dec;19(12):1299-1308
pubmed: 30374129
PLoS One. 2011 Mar 15;6(3):e17765
pubmed: 21423577
PLoS One. 2019 Feb 19;14(2):e0212295
pubmed: 30779801
Emerg Infect Dis. 2011 Jun;17(6):1107-9
pubmed: 21749782
J Infect Dis. 2014 Nov 15;210(10):1649-57
pubmed: 24907383
Lancet. 2000 Jan 29;355(9201):369-73
pubmed: 10665557
Clin Infect Dis. 2012 Sep;55(6):816-24
pubmed: 22700830
Vaccine. 2018 Nov 19;36(48):7369-7376
pubmed: 30352744
Int J Infect Dis. 2019 Sep;86:73-81
pubmed: 31247341
Hum Vaccin Immunother. 2016;12(2):344-50
pubmed: 26647277
Emerg Infect Dis. 2004 Oct;10(10):1713-20
pubmed: 15504255
Nat Commun. 2019 Jul 16;10(1):3060
pubmed: 31311921
Antibiotics (Basel). 2016 Jun 14;5(2):
pubmed: 27314398
Clin Infect Dis. 2014 May;58(10):1369-76
pubmed: 24621951
Nat Rev Microbiol. 2010 Jan;8(1):15-25
pubmed: 19946288
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Clin Microbiol Infect. 2015 Nov;21(11):1018.e9-1018.e15
pubmed: 26231980
Infect Immun. 2005 Nov;73(11):7718-26
pubmed: 16239576
Bull World Health Organ. 2012 Jan 1;90(1):12-9
pubmed: 22271960
BMC Biol. 2019 Nov 7;17(1):87
pubmed: 31699101
PLoS One. 2019 Apr 5;14(4):e0214207
pubmed: 30951544
FEBS Lett. 2016 Nov;590(21):3705-3720
pubmed: 27730630
J Infect Dis. 2016 Dec 1;214(11):1700-1711
pubmed: 27630199
Vaccine. 2017 Apr 4;35(15):1817-1827
pubmed: 28284682
Emerg Infect Dis. 2011 Jul;17(7):1240-7
pubmed: 21762578
PLoS Pathog. 2017 Dec 21;13(12):e1006665
pubmed: 29267378
PLoS One. 2016 Feb 10;11(2):e0149104
pubmed: 26863135
BMC Res Notes. 2014 Jan 10;7:26
pubmed: 24410938
Lancet Infect Dis. 2017 Nov;17(11):1133-1161
pubmed: 28843578
PLoS One. 2009 Aug 13;4(8):e6621
pubmed: 19675669
Philos Trans R Soc Lond B Biol Sci. 2015 Aug 19;370(1675):
pubmed: 26150660
mBio. 2012 Sep 25;3(5):
pubmed: 23015738
Biomed Res Int. 2020 Jan 3;2020:2032057
pubmed: 31998782
PLoS One. 2013 Jul 19;8(7):e69783
pubmed: 23894538
mBio. 2019 Jul 2;10(4):
pubmed: 31266874
Clin Microbiol Rev. 2012 Jul;25(3):409-19
pubmed: 22763632
Emerg Infect Dis. 2019 Nov;25(11):2040-2047
pubmed: 31625844
Pediatr Infect Dis J. 2007 May;26(5):416-22
pubmed: 17468652
Infect Immun. 1998 Feb;66(2):820-2
pubmed: 9453647